Autoimmune Haemolytic Anemia Market Forecast 2016-2026 - USA, France, Germany, Italy, Spain, UK, Brazil and Japan

Dublin, Aug. 10, 2016 -- Research and Markets has announced the addition of the "Autoimmune Haemolytic Anemia Forecast in 8 Major Markets 2016-2026" report to their offering.

Autoimmune haemolytic anaemia (AIHA) is an immune disorder caused by auto-antibodies against unmodified autologous red blood cells and can range in presentation from a mild illness to a rapidly fatal severe condition.

This report provides the current incident population for AIHA across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of AIHA's have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for AIHA include:

- Lymphoproliferative conditions:
- - CLL
- - HL
- - NHL
- Myeloproliferative conditions:
- - Multiple myeloma
- - Myelofibrosis
- - MGUS
- Autoimmune conditions:
- - RA
- - SLE
- - Polyarteritis nodosa
- Infections:
- - Pneumonia & Tuberculosis
- - Syphilis
- - Epstein-Barr
- - Chronic active hepatitis
- - Mononucleosis

Reasons to Buy:

- Able to quantify patient populations in global AIHA's market to target the development of future products, pricing strategies and launch plans.
- Gain further insight into the incidence of the subdivided types of AIHA and identify patient segments with high potential.
- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
- Provide a level of understanding on the impact from specific co-morbid conditions on AIHA's incident population.
- Identify sub-populations within AIHA which require treatment.
- Gain an understanding of the specific markets that have the largest number of AIHA patients.

Key Topics Covered:

1. List of Tables and Figures

2. Introduction

3. Cause of the Disease

4. Risk Factors & Prevention

5. Diagnosis of the Disease

6. Variation by Geography/Ethnicity

7. Disease Prognosis & Clinical Course

8. Clinical Management of AIHA
- Transfusion therapy in AIHA

9. Key Co-morbid Conditions/Features Associated with the Disease

10. Methodology for Quantification of Patient Numbers

11. Top-Line Incidence for AIHA

12 Subtypes of AIHA patients
- Warm AIHA patients
- Cold AIHA patients
- Mixed-type AIHA patients

13. Market Forecast for AIHA
- 1st Line Treatment Options within Warm & Mixed-type AIHA
- 2nd Line Treatment Options within Warm & Mixed-type AIHA
- 1st Line Treatment Options within Cold AIHA
- 2nd Line Treatment Options within Cold AIHA
- Requirement for Blood Transfusions within AIHA

14. Methodology for Forecast Figures

15. Abbreviations used in the report

16. Patient-Based Offering

17. Online Pricing Data and Platforms

18. References

19. Appendix

For more information visit http://www.researchandmarkets.com/research/c755wk/autoimmune

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716

         Sector: Hematology